Researchers in London conducted and completed a clinical trial of psilocybin-assisted therapy at a public health care clinic. The study findings, published in Nature Medicine, demonstrate that administering psilocybin to patients with depression is feasible within real-world clinical settings.Why It’s Relevant
Psilocybin-assisted therapy is a promising approach for treatment-resistant depression, but it’s a time- and resource-intensive therapy that may be difficult to carry out in community settings. While industry-funded clinical trials of psilocybin are well-controlled and recruit a select population that maximizes the chance of success, this current effort was sponsored by the National Health Service’s South London and Maudsley Foundation Trust.
By the Numbers
- In terms of operational success, 165 adults with treatment-resistant depression were approached, of whom 75 consented (46%) to participate. Of that group, 60 adults (80%) met eligibility requirements and entered the study.
- Participants were randomly assigned one dose of 25mg psilocybin or placebo, followed by a six-hour therapy session, then six integration sessions across six weeks. Overall, 59 of 60 participants completed all follow-up visits.
- By week three, depressive symptoms—measured on the Montgomery-Asberg Depression Rating Scale—were 10.4 points lower among adults who received psilocybin versus those on placebo; the superiority was maintained at week six.
- Psilocybin was well tolerated. Side effects were mostly mild, and there were no indications of emerging suicidality or mania.
The Other Side
Given psilocybin’s mental effects, there was no realistic way to blind participants as to which treatment they received, particularly as study investigators chose a completely inert placebo to better assess psilocybin-related side effects. Though this study was publicly funded, half of the trial took place at a refurbished community health care and research center partially funded by psilocybin manufacturer COMPASS Pathways (under a separate agreement).
Takeaway Message
The researchers noted that the feasibility, efficacy, and safety data are especially encouraging given that study participants had been ill with depression for about 20 years on average and had unsuccessfully tried a wide range of interventions. The findings support the development of larger clinical trials within public health settings.
Related Information
Source
James J. Rucker, et al. Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. Nature Medicine. Published August 6, 2026. doi:10.1038/s41591-026-04541-0
(Image: Getty Images/iStock/Cannabis-Pic)
